Simcere Pharmaceutical Group reported significantly improved Q2 financials today, but the results came in below analysts' estimates and the company reduced its guidance for full-year 2008. The disappointments caused a 4% selloff in the company’s stock price. Simcere blamed the shortfall on two problems: Endu revenue growth was lower than expected because the company restructured its Endu sales force. Also, Simcere is giving away Endu to accelerate participation in a Phase IV clinical trial of the drug, resulting in lower-than-projected sales. More details...

Stock Symbol: (NYSE: SCR)